Do ACE inhibitors provide protection for the heart in the clinical setting of acute myocardial infarction?

Drugs

Volumn 54, Issue SUPPL.5, 1997, Pages 48-58

  Megarry, S G ^a   Sapsford, R ^a   Hall, A S ^a   Ball, S G ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; CAPTOPRIL; CATECHOLAMINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL;

ACUTE HEART INFARCTION; ADRENERGIC SYSTEM; CELL VIABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL RATE;

ANIMALIA;

EID: 0030656602     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199700545-00008     Document Type: Review

References (64)

1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60
2. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402
3. White HD, Norris RM, Brown MA, et al. Left ventricular endsystolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76: 44-51
4. Touboul P, Andre-Fouet X, Leizorovicz A, et al. For The Groupe d'Etude du Pronostic de l'Infarctus du Myocarde (GREPI). Risk stratification after myocardial infarction. A reappraisal in the era of thrombolysis. Eur Heart J 1997; 18: 99-107
5. The AIRE Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8
6. Pfeffer MA, Braunwald E, Moye LA, et al. on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669-77
7. Swedberg K, Held P, Kjekshus J, et al. on behalf of the CONSENSUS II Study Group. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. N Engl J Med 1992; 327: 678-84
8. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6 week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 342: 1115-22
9. Fourth International Study of Infarct Survival Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85
10. Ambrosioni E, Borghi C, Magnani B for the Survival of Myocardial Infarction Long Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332: 80-5
11. Lisheng L, Liu LS, Wang W, et al. for the Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995; 345: 686-7
12. The TRACE Study Group. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-6
13. Benjamin IJ, Jalil JE, Tan LB, et al. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res 1989; 65: 657-70
14. Tan LB, Jalil JE, Pick R, et al. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991; 69: 1185-95
15. Weber KT, Brilla CG. Myocardial fibrosis and the renin-angiotensin aldosterone system. J Cardiovasc Pharmacol 1992; 20 Suppl. 1: S48-54
16. Rutherford JD, Pfeffer MA, Moye LA, et al. on behalf of the SAVE Investigators. Effects of captopril on ischaemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. Circulation 1994; 90: 1731-8
17. ISIS-I (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction. Lancet 1986; II: 57-66
18. Pedersen TR and the Norwegian Multicenter Study Group. Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801-7
19. Cleland JGF, Erhardt L, Murray G, et al. on behalf of the AIRE Study Investigators. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J 1997; 18: 41-51
20. Packer M. Lack of relation between ventricular arrhythmias and sudden death in patients with chronic heart failure. Circulation 1992; 85 Suppl. I: I-50-I-56
21. Hall AS, Gray D, Tan LB, et al. ACE inhibitors for myocardial infarction and unstable angina [letter]. Lancet 1993; 341: 1547
22. HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomised trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 1996; 12(2): 127-37
23. The QUinapril Ischaemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention. Cadiovasc Drugs Ther 1993; 7 (2): 273-82
24. Pepine CJ. Ongoing clinical trials of angiotensin converting enzyme inhibitors for the treatment of coronary artery disease in patients with preserved left ventricular function. J Am Coll Cardiol 1996; 27: 1048-52
25. Preliminary results presented orally by B. Pitt for the QUIET investigators, at the Hotline Session of the European Society of Cardiology, Birmingham NEC, Aug 1996
26. Angiotensin converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996; 94 (3): 258-65
27. Tan LB, Hall AS. Myocardial protection. In: Bowen HH, editor. Cardiovascular reparation and protection. Kent UK: Publishing Initiative Books, 1995: 86
28. Olivetti G, Melissari M, Capasso JM, et al. Cardiomyopathy and the ageing human heart. Myocyte loss and reactive cellular hypertrophy. Circ Res 1991; 68: 1560-8
29. Gavras H, Kremer D, Brown JJ, et al. Angiotensin and norepinephrine induced myocardial lesions: experimental and clinical studies in rabbits and man. Am Heart J 1975; 89: 321-32
30. Tennant R, Wiggers CJ. The effect of coronary occlusion on myocardial contraction. Am J Physiol 1935; 112: 351-61
31. Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischaemic ventricular dysfunction. Circulation 1982; 66: 1146-9
32. Hutchins GM, Bulkley BH. Infarct expansion versus extension: two different complications of acute myocardial infarction. Am J Cardiol 1978; 41: 1127-32
33. Pirolo JS, Hutchins GM, Moore GW. Inward expansion: pathologic analysis of 204 patients with a single myocardial infarct. J Am Coll Cardiol 1986; 7: 349-54
34. Pfeffer MA, Pfeffer JM, Steinberg C, et al. Survival after experimental myocardial infarction: beneficial effects of long term therapy with captopril. Circulation 1985; 72: 406-12
35. Pfeffer MA, Lamas GA, Vaughan DE, et al. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988; 319: 80-6
36. Sharpe N, Murphy J, Smith H, et al. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988; 1: 255-9
37. Lamas GA, Pfeffer MA, Braunwald E. Patency of the infarct-related coronary artery and ventricular geometry. Am J Cardiol 1991; 68: 41-51D
38. Maseri A, Chierchia S, Davies G. Pathophysiology of coronary occlusion in acute infarction. Circulation 1986; 73: 233-9
39. Califf RM, Topol EJ, Gersh BJ. From myocardial salvage to patient salvage in acute myocardial infarction: role of reperfusion therapy. J Am Coll Cardiol 1989; 14: 1382-8
40. Gaudron P, Eilles C, Kugler I, et al. Progressive left ventricular dysfunction and remodelling after myocardial infarction. Potential mechanisms and early predictors. Circulation 1993; 87: 755-3
41. Vaughan DE, Pfeffer MA. Angiotensin converting enzyme inhibitors and cardiovascular remodelling. Cardiovas Res 1994; 28: 159-65
42. Bing OLH, Brooks WW, Conrad CH, et al. Myocardial mechanics of infarcted and hypertrophied non-infarcted myocardium following experimental coronary artery occlusion. In: Cardiac adaptation to haemodynamic overload training and stress. Darmstedt: Dr D. Steinkapff Verlag, 1983: 235-44
43. Mitchell GF, Lomas GA, Vaughan DE, et al. Left ventricular remodelling in the year following first anterior myocardial infarction in a quantitative analysis of alterations in contractile segment lengths and ventricular shape. J Am Coll Cardiol 1982; 19: 1136-44
44. Ito H, Yu H, Tomooka T, et al. Incidence and time course of left ventricular dilatation in the early convalescent stage of reperfused anterior wall acute myocardial infarction. Am J Cardiol 1994; 73: 539-43
45. Baroldi G. Morphologic forms of myocardial necrosis related to myocardial cell function. In: Silver MD, editor. Cardiovascular pathology. 2nd ed. New York: Churchill Livingstone, 1991
46. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997; 336: 1131-41
47. Tan LB, Hall AS. Cardiac remodelling. Br Heart J 1994; 72: 315-6
48. Rouleau JL, Packer M, Moye L, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994; 24 (3): 583-91
49. Swedberg K, Eneroth P, Kiekshus J, et al. for the CONSENSUS trial group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730-6
50. Francis GS, Cohn JN, Johnson G, et al. for the V-HeFT VA Cooperative Studies Group. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. Circulation 1993; 87 Suppl. VI: VI-40-VI-48
51. Mann DL, Kent RL, Parsons B, et al. Adrenergic effects on the biology of the adult mammalian cardiomyocyte. Circulation 1992; 85: 790-804
52. Croizier I, Ikram H, Awan N, et al. Losartan in heart failure: haemodynamic effects and tolerability. Circulation 1995; 91: 691-7
53. Klinger G, Jaramillo N, Ikram H, et al. Effects of losartan on exercise capacity, morbidity and mortality in patients with symptomatic heart failure [abstract]. J Am Coll Cardiol 1997; 29 Suppl. A: 205A
54. Pitt B, Segal R, Martinez FA, et al. on behalf of the ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-52
55. Hutchins GM, Bulkley BH. Infarct expansion versus extension: two different complications of acute myocardial infarction Am J Cardiol 1978; 41: 1127-32
56. Davies MJ, Woolf N. Atherosclerosis in ischaemic heart disease. Vol. 1. London: Science Press, 1990: 2.29
57. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 Trial. J Am Coll Cardiol 1996; 27 337-44
58. Hall AS. ACE inhibitors post-MI: the case for delayed, selective long term treatment. Controv Cardiol 1995; 6 (2): 5-8
59. Konstam MA, Rousseau MF, Kronenberg MV, et al for the SOLVD Investigators. Effects of the angiotensin converting enzyme inhibitor enalapril on the long term progression of left ventricular dysfunction in patients with heart failure. Circulation 1992; 86: 431-8
60. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and heart failure. N Engl J Med 1991; 325: 293-302
61. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325-303-10
62. Ball SG, Hall AS, Murray GD. ACE-inhibition, atherosclerosis and myocardial infarction - the AIRE Study in practice. Eur Heart J 1994: 15 Suppl. B: 20-5
63. Hall AS, Sapsford R, Megarry SG, et al. Inhibition of the renin angiotensin system after acute myocardial infarction - treat first, select later? Heart 1996; 76 Suppl. 3: 73-8
64. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35